Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Otsuka and Lundbeck to commence phase III trials of Alzheimer’s drug

Otsuka and Lundbeck to commence phase III trials of Alzheimer’s drug

14th October 2013

Otsuka is allying with Lundbeck to carry out a series of four phase III trials of a promising new therapy for Alzheimer's disease.

The next stage of the development programme of the Lu AE58054 compound will include around 3,000 patients in 17 countries across the four trials, with the aim of assessing the safety and efficacy of the drug as an add-on therapy for Alzheimer's.

Several doses of Lu AE58054 – ranging from ten to 60 mg – will be used in combination with donepezil in order to explore the effect of Lu AE58054 in mild to moderate Alzheimer's disease as an adjunctive therapy to acetylcholinesterase inhibitors.

The first of the four trials will involve 930 patients and is expected to last up to three years.

Dr William Carson, president and chief executive officer at Otsuka Pharmaceutical Development and Commercialisation, said: "Use of the serotonin 5-HT6 antagonism mechanism against the cognitive effects of Alzheimer's is a promising hypothesis that we will seek to validate more fully in these phase III trials."

The news comes after Otsuka announced the completion of its takeover of Astex Pharmaceuticals earlier this month.ADNFCR-8000103-ID-801648860-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.